99 related articles for article (PubMed ID: 32734520)
1. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.
Groen EJ; Hudecek J; Mulder L; van Seijen M; Almekinders MM; Alexov S; Kovács A; Ryska A; Varga Z; Andreu Navarro FJ; Bianchi S; Vreuls W; Balslev E; Boot MV; Kulka J; Chmielik E; Barbé E; de Rooij MJ; Vos W; Farkas A; Leeuwis-Fedorovich NE; Regitnig P; Westenend PJ; Kooreman LFS; Quinn C; Floris G; Cserni G; van Diest PJ; Lips EH; Schaapveld M; Wesseling J;
Breast Cancer Res Treat; 2020 Oct; 183(3):759-770. PubMed ID: 32734520
[TBL] [Abstract][Full Text] [Related]
2. The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.
Alaeikhanehshir S; Schmitz RSJM; van den Belt-Dusebout AW; van Duijnhoven FH; Verschuur E; van Seijen M; Schaapveld M; Lips EH; Wesseling J;
Breast Cancer Res Treat; 2024 Feb; 204(1):61-68. PubMed ID: 37964135
[TBL] [Abstract][Full Text] [Related]
3. Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.
Almekinders MMM; Schaapveld M; Thijssen B; Visser LL; Bismeijer T; Sanders J; Isnaldi E; Hofland I; Mertz M; Wessels LFA; Broeks A; Hooijberg E; Zwart W; Lips EH; ; Desmedt C; Wesseling J
NPJ Breast Cancer; 2021 Mar; 7(1):31. PubMed ID: 33753731
[TBL] [Abstract][Full Text] [Related]
4. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.
Rakovitch E; Gray R; Baehner FL; Sutradhar R; Crager M; Gu S; Nofech-Mozes S; Badve SS; Hanna W; Hughes LL; Wood WC; Davidson NE; Paszat L; Shak S; Sparano JA; Solin LJ
Breast Cancer Res Treat; 2018 Jun; 169(2):359-369. PubMed ID: 29388015
[TBL] [Abstract][Full Text] [Related]
5. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control study.
Rask G; Wadsten C; Acs B; Hartman J; Fredriksson I; Garmo H; Wärnberg F; Sund M
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38395442
[TBL] [Abstract][Full Text] [Related]
6. Interrater reliability of a method to assess hypothalamic involvement in pediatric adamantinomatous craniopharyngioma.
Whelan R; Prince E; Mirsky DM; Naftel R; Bhatia A; Pettorini B; Avula S; Staulcup S; Alexander AL; Meier M; Hankinson TC
J Neurosurg Pediatr; 2019 Oct; 25(1):37-42. PubMed ID: 31604324
[TBL] [Abstract][Full Text] [Related]
7. Adapting the Client Priority Rating Scale to better fit the sexual health counselling setting: a quality improvement study.
Coote K; O'Neill F; Slavich E
Sex Health; 2024 Feb; 21():. PubMed ID: 38408426
[TBL] [Abstract][Full Text] [Related]
8. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
Shaaban AM; Hilton B; Clements K; Provenzano E; Cheung S; Wallis MG; Sawyer E; Thomas JS; Hanby AM; Pinder SE; Thompson AM;
Br J Cancer; 2021 Mar; 124(5):1009-1017. PubMed ID: 33199800
[TBL] [Abstract][Full Text] [Related]
9. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
Pawloski KR; Tadros AB; Sevilimedu V; Newman A; Gentile L; Zabor EC; Morrow M; Van Zee KJ; Kirstein LJ
Breast Cancer Res Treat; 2021 Apr; 186(3):617-624. PubMed ID: 33675490
[TBL] [Abstract][Full Text] [Related]
10. Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
Byng D; Retèl VP; Schaapveld M; Wesseling J; van Harten WH;
Breast Cancer Res Treat; 2021 May; 187(1):187-196. PubMed ID: 33389397
[TBL] [Abstract][Full Text] [Related]
11. Tools to Guide Radiation Oncologists in the Management of DCIS.
Leonardi MC; Zerella MA; Lazzeroni M; Fusco N; Veronesi P; Galimberti VE; Corso G; Dicuonzo S; Rojas DP; Morra A; Gerardi MA; Lorubbio C; Zaffaroni M; Vincini MG; Orecchia R; Jereczek-Fossa BA; Magnoni F
Healthcare (Basel); 2024 Apr; 12(7):. PubMed ID: 38610216
[TBL] [Abstract][Full Text] [Related]
12. Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.
Alaeikhanehshir S; Voets MM; van Duijnhoven FH; Lips EH; Groen EJ; van Oirsouw MCJ; Hwang SE; Lo JY; Wesseling J; Mann RM; Teuwen J;
Cancer Imaging; 2024 Apr; 24(1):48. PubMed ID: 38576031
[TBL] [Abstract][Full Text] [Related]
13. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.
Wang J; Li B; Luo M; Huang J; Zhang K; Zheng S; Zhang S; Zhou J
Signal Transduct Target Ther; 2024 Apr; 9(1):83. PubMed ID: 38570490
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.
Sobral-Leite M; Castillo S; Vonk S; Melillo X; Lam N; de Bruijn B; Hagos Y; Sanders J; Almekinders M; Visser L; Groen E; Kristel P; Ercan C; Azarang L; Yuan Y; ; Menezes R; Lips E; Wesseling J
Res Sq; 2023 Dec; ():. PubMed ID: 38168198
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Schmitz RSJM; Engelhardt EG; Gerritsma MA; Sondermeijer CMT; Verschuur E; Houtzager J; Griffioen R; Retèl V; Bijker N; Mann RM; van Duijnhoven F; Wesseling J; Bleiker EMA;
Eur J Cancer; 2023 Oct; 192():113276. PubMed ID: 37657228
[TBL] [Abstract][Full Text] [Related]
16. Positive surgical margins after breast-conserving surgery for ductal carcinoma in-situ: does histologic grade or estrogen receptor status matter?
Fauveau LR; Dao TN; Wallace LB; Mamawala MK; Obaid A; Waddimba AC; Grant MD
Breast Cancer Res Treat; 2023 Jun; 199(2):215-220. PubMed ID: 37027122
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cytokine-enriched microenvironment plays key roles in the development of breast cancers.
Takeuchi Y; Gotoh N
Cancer Sci; 2023 May; 114(5):1792-1799. PubMed ID: 36704829
[TBL] [Abstract][Full Text] [Related]
18. Machine Learning of Raman Spectroscopy Data for Classifying Cancers: A Review of the Recent Literature.
Blake N; Gaifulina R; Griffin LD; Bell IM; Thomas GMH
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741300
[TBL] [Abstract][Full Text] [Related]
19. Radiological Underestimation of Tumor Size as a Relevant Risk Factor for Positive Margin Rate in Breast-Conserving Therapy of Pure Ductal Carcinoma In Situ (DCIS).
Schultek G; Gerber B; Reimer T; Stubert J; Hartmann S; Martin A; Stachs A
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625972
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
